Karyopharm Therapeutics (NASDAQ:KPTI) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a hold rating to a sell rating in a research report report published on Saturday morning.

Several other brokerages also recently commented on KPTI. Piper Sandler lowered their price target on Karyopharm Therapeutics to $7.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Karyopharm Therapeutics in a report on Tuesday, June 9th. Robert W. Baird lowered shares of Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 target price on the stock. in a research note on Friday, July 31st. Weiss Ratings upgraded shares of Karyopharm Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $16.00 target price on shares of Karyopharm Therapeutics in a report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Karyopharm Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Karyopharm Therapeutics Stock Performance

KPTI opened at $2.02 on Friday. The company has a market cap of $45.77 million, a PE ratio of -0.15 and a beta of 0.89. The stock has a 50-day moving average of $7.47 and a 200-day moving average of $7.85. Karyopharm Therapeutics has a 52-week low of $1.80 and a 52-week high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($2.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.95). The company had revenue of $33.43 million during the quarter, compared to analyst estimates of $32.19 million. On average, research analysts predict that Karyopharm Therapeutics will post -4.28 earnings per share for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several hedge funds have recently made changes to their positions in KPTI. Bank of New York Mellon Corp acquired a new stake in Karyopharm Therapeutics during the second quarter worth about $559,000. Avidity Partners Management LP raised its holdings in Karyopharm Therapeutics by 244.6% in the 1st quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock valued at $2,583,000 after acquiring an additional 329,175 shares in the last quarter. Royal Bank of Canada lifted its position in shares of Karyopharm Therapeutics by 4.1% in the 1st quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock worth $336,000 after acquiring an additional 2,399 shares during the period. Commodore Capital LP bought a new stake in shares of Karyopharm Therapeutics in the 1st quarter worth approximately $10,862,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Karyopharm Therapeutics during the 1st quarter worth approximately $108,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.